Aqilion's licensing journey: From Merck partnership to new opportunities

Be extremely meticulous with your scientific data, but spend just as much time and effort on business development. That piece of advice comes from Aqilion's CEO...

Icelandic pharmaceutical company Alvotech to list on Nasdaq Stockholm

One of Iceland's largest companies, the pharmaceutical firm Alvotech, has announced its intention to list on Nasdaq Stockholm.

“Research is always a lot of failures and a few successes”

Gene therapies open up fantastic possibilities, but they are also extremely expensive to produce. Genenova aims to change that and make the treatments accessibl...

Trump in new push to lower drug prices

U.S. President Donald Trump announced on Sunday that he plans to sign an executive order to lower the cost of prescription drugs to the same levels paid in othe...

Quality assurance for research and development of medical devices

Overcome the hurdles of research, development, and QA lab environments within the regulated medical technology industry.

Ledarskifte i GSK – Emma Walmsley lämnar efter åtta år

Läkemedelsjätten GSK:s vd Emma Walmsley lämnar efter åtta år på posten. Hon ersätts med Luke Miels, som idag är bolagets Chief Commercial Officer.

Integrated solutions for liquid handling

Greater efficiency for manufacturers in laboratory automation and many other industries

Del 3 av Advance serien: Design

Ta reda på hur du kan omvandla en audit till en konkret lösning. Spirax Sarcos designfas ger dig allt du behöver för att implementera ett optimerat och framtids...

An organ seldom in the spotlight – but utterly vital

The kidneys consist of more than 40 types of cells and have more functions in the body than most people know. Julie Williams leads AstraZeneca’s work in preclin...

The Future of Swedish & Danish Life Science (2026)

The race between new alzheimer’s drugs Kisunla and Leqembi heats up

Kisunla or Leqembi? The rivalry between Eli Lilly and Bioarctic is intensifying. Where one drug gains approval, the other falls behind. Here's a look at the mar...

Bioscience – Groundbreaking Research & Diagnostics: Stockholm (2026)

Implantatföretags grundare lämnar vd-posten

Medtechbolaget Integrums grundare Rickard Brånemark lämnar vd-posten och får i stället en rådgivande roll i bolaget. Ny tillförordnad vd är styrelseledamoten Scott Flora.

Sana Alajmovic lämnar Sigrid för nytt vd-jobb

Sana Alajmovic, medgrundare och vd för Sigrid Therapeutics, lämnar bolaget för en vd-post i Enzymatica.

The business coach: “We need to learn from our mistakes”

The past year has been challenging for many biotech companies, with several comapanies facing financial stress and bankruptcy. To understand how entrepreneurs c...

Ukraine war fuels rise of totally resistent bacteria

War-torn Ukraine is not just suffering from hostile attacks from a foreign aggressor, but also from the threat of a totally resistant and contagious bacteria.

Sustainability at Festo

On the Way to the Net Zero Era - New Sustainability Report published

Eli Lilly värvar toppforskaren Kaj Blennow – ska leda Alzheimerprojekt

Eli Lilly rekryterar Kaj Blennow, en av Sveriges och världens främsta forskare inom Alzheimers sjukdom, till en post som Vice President of Neuroscience Biomarker Development.

Quality solutions for medical device R&D applications

From R&D to the quality assurance of series production in medical device manufacturing.

Clinigen Clinical Supplies Management GmbH

GSK acquires oncology research company

GSK acquires the American biotechnology company Idrx for up to 1.15 billion dollars.

Who pays for Rebecca Doe – and all of us?

Anna Törner on how easily we get used to the idea that healthcare is free - when it really is about how and who pays for it

Life science trends 2025 – The economy

Upcoming patent expirations are driving pharmaceutical companies to acquire in 2025. In Sweden, we may be on our way to brighter times and fewer bankruptcies. T...

To build trust, one must be able to say “I don’t know” – whether human or AI

Will AI strengthen or break down trust? It depends on whether we can understand and accept its limitations, and our own, writes Sarah Lidé in a column.